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Abstract
Background: Obesity has long been associated with postmenopausal breast cancer risk and more recently with
premenopausal breast cancer risk. We previously observed that nipple aspirate fluid (n) levels of prostate specific
antigen (PSA) were associated with obesity. Serum (s) levels of adiponectin are lower in women with higher body mass
index (BMI) and with breast cancer. We conducted a prospective study of obese women who underwent gastric bypass
surgery to determine: 1) change in n- and s-adiponectin and nPSA after surgery and 2) if biomarker change is related to
change in BMI. Samples (30-s, 28-n) and BMI were obtained from women 0, 3, 6 and 12 months after surgery.
Findings: There was a significant increase after surgery in pre- but not postmenopausal women at all time points
in s-adiponectin and at 3 and 6 months in n-adiponectin. Low n-PSA and high s-adiponectin values were highly
correlated with decrease in BMI from baseline.
Conclusions: Adiponectin increases locally in the breast and systemically in premenopausal women after gastric
bypass. s-adiponectin in pre- and nPSA in postmenopausal women correlated with greater weight loss. This study
provides preliminary evidence for biologic markers to predict weight loss after gastric bypass surgery.
Background and Hypotheses
Thirty to 50% of postmenopausal breast cancer deaths
in the U.S. have been attributed to being overweight [1].
Greater hip circumference has been linked to increased
risk of premenopausal breast cancer [2]. It has been sug-
gested that a reduction in obesity could significantly
decrease breast cancer incidence [3]. In postmenopausal
women without [4] and with breast cancer [5], high
body mass index (BMI) is associated with increased con-
centrations of circulating estradiol, estrone, and testos-
terone. Nonetheless, BMI serves as a breast cancer risk
factor independent of serum estrogen levels [6], suggest-
ing that mechanisms other than estrogen stimulation of
the breast influence breast cancer risk.
Adiponectin is an inflammatory cytokine found in and
secreted by adipose cells [7]. Adiponectin has potential
anticancer properties, including anti-inflammatory and
insulin-sensitizing effects [8]. Serum (s) adiponectin
levels have variously been associated inversely with both
pre- and postmenopausal [9], or only postmenopausal
[10] breast cancer risk. It has been postulated that local
production of adipokines within the breast stroma sur-
rounding epithelial cells may be directly linked to the
development and growth of breast cancer and be more
relevant to cancer risk than serum levels [11]. We are
not aware of a published report measuring adiponectin
in nipple aspirate fluid (n).
PSA, also known as kallikrein-related peptidase (KLK)3,
is used to screen for prostate cancer, a disease under hor-
monal influence. In women, we have found that nPSA is
regulated in the breast by steroid hormones [12], is inver-
sely associated with breast cancer risk [13], and is asso-
ciated with BMI in both pre- and post-menopausal women
with breast cancer [14]. Serum levels of PSA are very low
in women and often undetectable [15]. Our hypotheses
were that: adiponectin and PSA, proteins associated with
breast cancer, would change after obesity surgery, and that
t h ec h a n g ew o u l db er e l a t e dt oc h a n g ei nB M I .
Methods
Subjects and specimens
All subjects were female and included 25 (83.3%) Cauca-
sians and 5 (16.7%) African Americans. Twenty were
pre- and 10 postmenopausal. Median age of the group
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was 47.0 (range = 36.6-60.8). BMI was similar among pre-
(median = 47.0, range = 36.6-55.3) and postmenopausal
(median = 45.4, range = 38.3-60.8) women. All women
signed a University of Missouri Institutional Review Board
approved consent prior to undergoing baseline nipple
aspirate fluid and blood collection followed by Roux-en-Y
gastric bypass surgery. We were able to collect nipple aspi-
rate fluid from 28/30 (93%) women at baseline, from 25/28
(89%) women at 3 months, 25/29 (86%) women at 6
months, and 19/22 (86%) 12 months after surgery. Three
women missed one appointment (two women at 3
months, one woman at 6 months). No one dropped out of
the study until after the six month appointment, when
eight subjects dropped out. Nipple aspirate fluid and blood
procurement procedures were performed as previously
described [16]. Samples were snap frozen and stored at
-80°C until use. Capillary tubes containing nipple aspirate
fluid were crushed to release the fluid in 200 uL of a 0.1
M sodium bicarbonate solution.
Protein analyses
Adiponectin was analyzed using an ELISA kit from
LINCO Research, Inc. (St. Charles, MO) following the
manufacturer’s instructions. The detection limit for the
kit was 0.78 ng/ml. PSA was analyzed using a time-
resolved immunofluorometric assay with a detection
limit of 5 ng/L. The coefficient of variation for the adi-
ponectin and PSA assays were < 10% within the mea-
surement range. Total nipple aspirate fluid protein was
determined using a Pierce (Rockford, IL) BCE Protein
Assay Reagent kit. PSA values were controlled for total
nipple aspirate fluid protein, as has been our custom in
the past. Both s- and n-adiponectin were evaluated
based on total fluid volume, so that values in the two
body fluids could be compared.
Statistical analysis
Summary statistics including mean, standard deviation
and median were computed for the BMI and biomarkers
separately by menopausal status as well as for the com-
bined sample at pre surgery assessment and 3-, 6- and 12-
months post surgery. Both means and medians are
reported, means to provide standard deviations (SDs), and
medians because of the limited sample size and asym-
metric data, making the use of only means/SDs potentially
misleading. We based our tests of significance on medians
which is more conservative than on means. We feel this is
appropriate with a limited sample size. Spearman’s rank-
order correlation coefficients were used to evaluate the
association between absolute values and changes in BMI
and biomarkers. Changes from baseline in BMI and bio-
markers were evaluated using the Wilcoxon signed rank
nonparametric test. Differences in changes in BMI and
biomarkers by menopausal status were evaluated using the
Mann-Whitney nonparametric test.
Results
BMI significantly decreased over time for both pre- (p ≤
.001) and postmenopausal (p < .01) women at 3, 6 and
12 months post surgery, with percent excess weight
(BMI > = 25.0) slowing over time. Higher baseline BMI
negatively correlated (p < .05) with BMI decrease (com-
pared to baseline) at 3, 6 and 12 months, and decrease
i nB M Ia t3a n d6m o n t h s( p < .05 for both) correlated
with decrease at later time points.
Adiponectin is measurable in breast nipple aspirate fluid
Since we are unaware of a prior report documenting the
detection of adiponectin in nipple aspirate fluid, we first
determined if adiponectin was detectable, and if detect-
able the concentration of the marker in this fluid rela-
tive to serum. We detected a d i p o n e c t i ni na l ls e r u m
(range: premenopausal: 2913-18402 ng/mL; postmeno-
pausal: 4785-27179 ng/mL) and nipple aspirate fluid
(range: premenopausal: 131.1-3883 ng/mL; postmeno-
pausal: 212.2-4807 ng/mL) samples analyzed. Median n-
adiponectin levels were 5.3-8.2% of s-adiponectin in pre-
and 9.6-11.0% in postmenopausal women (Table 1).
Association of nipple aspirate fluid and serum samples
with BMI
nPSA did not consistently change over time (Table 1).
In pre- but not postmenopausal women, n-adiponectin
levels significantly increased at 3 and 6 months after
surgery, and s-adiponectin increased at all post surgery
time points.
Two biomarkers, nPSA and s-adiponectin, correlated
with decrease in BMI. At all time points, low nPSA cor-
related with BMI decrease in postmenopausal women
(Figure 1A). At 6 and 12 months after surgery, high s-
adiponectin (Figure 1B) correlated with BMI decrease in
premenopausal women (Table 2).
Discussion
The influence of obesity on postmenopausal breast can-
cer risk is well established, while the association with
premenpausal breast cancer risk is less certain [1].
Nonetheless, new evidence suggests that an increased
hip circumference is associated with premenopausal
breast cancer [2]. Multiple reports document that weight
loss after gastric bypass surgery leads to a reduced risk
of cancer, with the strongest effect on female obesity
related tumors [17]. This risk reduction is thought to
involve alterations in adipokines, sex steroid hormones
and other proteins [17], but the specific proteins that
influence risk and risk reduction after weight loss are
for the most part unknown.
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expression is a better predictor of breast cancer risk
than is expression in the circulation [15]. We demon-
strate that both n- and s-adiponectin increase with a
d e c r e a s ei nB M I ,t h a tt h et w oa r eh i g h l yc o r r e l a t e d6
months after surgery, and that these correlations are
greater in pre- than in postmenopausal women
We observed that higher levels of s-adiponectin in
premenopausal women and lower levels of nPSA in
postmenopausal women correlated with the amount of
Table 1 Biomarkers before and after gastric bypass surgery by menopausal status
Variable Menopausal Status Value Months since surgery
03 6 1 2
Nipple
aspirate
fluid
(n)PSA (ng/g) p
value ≤ .001,
***; p value
≤ .01, **; p
value ≤ .05,
*, compared
to baseline
Pre-
menopausal
Mean 2514.0 1080.3 4942.2 1379.4
Median 405.1 166.7 653.2 586.9
StDev 4049.7 2406.9 11470.0 2026.8
Samples 15 13 12 7
Post-
menopausal
Mean 1266.4 731.7 1130.5 643.2
Median 200.0 109.4 575.4 399.1
StDev 2831.6 1356.4 1748.7 1006.8
Samples 9 8 8 8
Total sample Mean 2046.1 947.5 3417.5 986.7
Median 315.7 144.3 653.2 510
StDev 3626.6 2037.1 8998.0 1553.0
Samples 24 21 20 15
n-
adiponectin
(ng/mL) p
value ≤ .001,
***; p value
≤ .01, **; p
value ≤ .05,
*, compared
to baseline
Pre-
menopausal
Mean 778.7 1118.9 1164.5 1293.7
Median 471.8 617.1* 808.8* 638.2
StDev 746.8 961.3 1091.9 1346.2
Samples 14 12 11 9
Post-
menopausal
Mean 1310.3 1323.1 1482.6 2056.8
Median 984.2 1168.5 1006.0 1204.2
StDev 992.9 903.0 1169.6 1933.4
Samples 8 6 8 7
Total sample Mean 972.0 1186.9 1298.5 1627.5
Median 690.9 817.1 808.8 894.8
StDev 861.6 920.6 1104.7 1617.0
Samples 22 18 19 16
Serum (s)-
adiponectin
(ng/mL) p
value ≤ .001,
***; p value
≤ .01, **; p
value ≤ .05,*,
compared to
baseline
Pre-
menopausal
Mean 7245.4 9090.9 10427.7 12103.8
Median 7366.0 9113.0*** 9846.5*** 12008.3*
StDev 2706.8 2997.5 3119.2 3551.7
Samples 18 17 17 8
Post-
menopausal
Mean 11925.6 11388.0 12370.0 13646.4
Median 8900.5 10968.0 10429.5 11944.5
StDev 7252.0 4829.7 4635.6 5408.2
Samples 10 9 9 7
Total sample Mean 8916.9 9886.1 11100.0 12823.6
Median 7406.3 9368.0** 10138.0** 11944.5**
StDev 5230.6 3802.2 3740.5 4413.3
Samples 28 26 26 15
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studied to determine the amount of weight that will be
l o s ta f t e rs u r g e r yf o rm o r b i do b e s i t yi n c l u d ep r e m o r b i d
weight, exercise, and psychosocial factors [18]. We are
not aware of a reliable marker present in the circulation
or organ specific fluid which has been shown to predict
change in BMI.
Our findings regarding adiponectin expression are
consistent with the premise that weight loss lowers
breast cancer risk. Higher levels of s-adiponectin [9] are
found in healthy women than in women with breast
cancer. Our observed increase in s-adiponectin at 12
months, as well as the inverse correlation of s-adiponec-
tin with BMI 6 and 12 months after gastric bypass sur-
gery, is similar to other reports [19]. Whereas median
breast milk adiponectin concentrations have been
reported to average 0.12% of matched serum [20], we
observed that n-adiponectin averaged 5.3-8.2% of
matched serum in pre- and 9.6-11.0% in postmenopau-
sal women, suggesting higher adiponectin levels are pre-
sent in the nonlactating than the lactating breast. While
speculative, higher adiponectin concentrations in the
nonlactating breast could lead to a greater effect of pro-
tein, which has anticancer properties [21].
There were limitations to our study, most notably a
limited sample set, especially in postmenopausal women.
Therefore, our findings are preliminary and require vali-
dation. Validation of our findings would suggest that
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Figure 1 Scatterplots illustrating change in BMI vs. A) nPSA
and B) s-adiponectin 12 months after surgery with separate
symbols for pre- and postmenopausal women.
Table 2 Spearman correlation coefficients (corr) after gastric bypass surgery
1
Samples/Correlation (Pvalue
1)
Biomarker
Current BMI Months Since Surgery 0 3 6 12
n-PSA Pre 15/-.013 13/-.32 12/-.074 7/-.43 (.34)
Post 9/-.32 8/.17 8/.21 7/.11
Total 24/-.20 21/-.19 20/.026 15/-.057
n-adiponectin Pre 14/.10 12/-.12 11/-.073 8/-.26
Post 8/.12 6/.14 8/.095 7/.14
Total 22/.076 18/.005 19/.053 15/-.15
s-adiponectin Pre 18/.28 17/.43 (.084) 17/-.20 8/-.17
Post 10/.030 9/-.083 9/.35 7/-.50 (.25)
Total 28/.19 26/.23 26/.13 15/-.28
BMI Δ
n-PSA Pre 13/-.45 (.12) 12/.028 7/.32
Post 8/.66 (.076) 8/.55 (.16) 8/.60 (.12)
Total 21/.19 20/.28 15/.38
n-adiponectin Pre 12/-.042 11/.28 8/-.33
Post 6/-.54 (.27) 8/.21 7/.29
Total 18/-.17 19/.15 15/.15
s-adiponectin Pre 17/.007 17/-.44 (.076) 8/-.67 (.071)
Post 9/-.27 9/-.15 7/.11
Total 26/.091 26/-.36 15/-.39
1: p values are shown only for correlations ≥ 0.4. Pre: pre-menopausal; Post: post-menopausal; Total: Total sample
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body fluids may be able to predict decrease in BMI after
gastric bypass surgery, and that when assessing these
markers, menopausal status should be considered.
Abbreviations
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